Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.32 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649950 | 0.89 | TAS1R3 (0.34) | TAS1R3TAS1R1TAS1R2CYP3A4ADCY8 | |
| SCHEMBL2650716 | 0.86 | RARA (0.34) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2651002 | 0.85 | TAS1R3 (0.32) | TAS1R3TAS1R1TAS1R2ADCY8ADCY1 | |
| SCHEMBL2650348 | 0.85 | TAS1R3 (0.32) | TAS1R3TAS1R1TAS1R2ADCY8ADCY1 | |
| SCHEMBL2650025 | 0.84 | GCK (0.33) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2650469 | 0.84 | GCK (0.32) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2650318 | 0.84 | GCK (0.32) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2648958 | 0.82 | GCK (0.48) | — | |
| SCHEMBL2650499 | 0.81 | GCK (0.35) | — | |
| SCHEMBL2652542 | 0.76 | EPHX2 (0.34) | TAS1R3TAS1R1TAS1R2ADCY8ADCY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311504-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014312-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |